Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AKP 002

Next Previous
X
Search
Drug Profile

AKP 002

Alternative Names: AKP-002; ASP-4901

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ASKA Pharmaceutical
  • Developer Astellas Pharma
  • Class Urologics
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 11 Feb 2015 Discontinued - Phase-II for Benign prostatic hyperplasia in Japan (PO)
  • 31 Aug 2013 Phase-II clinical trials in Benign prostatic hyperplasia in Japan (PO)
  • 01 Aug 2011 Phase I development in Benign prostatic hyperplasia is ongoing in Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top